Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Beigene, Betterlife, Biocon, Eli Lilly, Everest Medicines, I-Mab, Incyte, Junshi, Kyowa Kirin, Nrx, Scancell, Takeda, Transcenta, Viatris.